Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
KIMS already have a multi-specialty hospital and gastro unit at Vizag
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Subscribe To Our Newsletter & Stay Updated
